Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone

The purpose of this study is to evaluate the safety and efficacy of administration of intratumoral IP-001 injection at different dosages (volume and concentration) following local microwave ablation (MWA) or surgical resection and ablation in patients with hepatocellular carcinoma (HCC).

Trial Details

NCT ID
NCT06526338
Phase
PHASE2
Sponsor
Robert C. Martin
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • 1.0% IP-001 for injection
  • Surgical Resection and Local Ablation
  • Local Ablation Alone
Locations (sample)
  • Louisville, Kentucky, United States|38.25424,-85.75941

Key Eligibility Criteria

  • Age ≥ 18 years at time of signing Informed Consent.
  • Has a diagnosis of hepatocellular carcinoma (HCC) documented radiologically by American Association for the Study of Liver Diseases (AASLD) criteri…
  • Has a treatment plan to receive a curative ablation (MWA only) or a curative surgical resection and ablation, or where the patient may benefit from…
  • Has HCC with intermediate, high or very high risk of recurrence.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →